Literature DB >> 2471521

Angiotensin 'antipeptides': (-)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist.

G J Moore1, R C Ganter, K J Franklin.   

Abstract

(-)mRNA complementary to human angiotensin II (+)mRNA encodes the 'antipeptide' Glu-Gly-Val-Tyr-Val-His-Pro-Val which is structurally related to angiotensin II. Angiotensin II 'antipeptide' (antiANG II) and the desglutamyl heptapeptide (antiANG III) are Type I antagonists which inhibit the contractile action of angiotensin at smooth muscle receptors by binding to a negative modulatory site on the angiotensin receptor which is distinct from the angiotensin binding site. These findings may illustrate that the inhibitory binding site on the angiotensin receptor exists to accomodate a naturally occurring inhibitor(s), which is encoded by the DNA strand complementary to that encoding angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471521     DOI: 10.1016/s0006-291x(89)80157-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Enkephalin antisense peptides: design, synthesis, and biological activity.

Authors:  P K Misra; W Haq; S B Katti; K B Mathur; R Raghubir; G K Patnaik; B N Dhawan
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

3.  Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2.

Authors:  Harry Ridgway; Graham J Moore; Thomas Mavromoustakos; Sotirios Tsiodras; Irene Ligielli; Konstantinos Kelaidonis; Christos T Chasapis; Laura Kate Gadanec; Anthony Zulli; Vasso Apostolopoulos; Russell Petty; Ioannis Karakasiliotis; Vassilis G Gorgoulis; John M Matsoukas
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

4.  Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System.

Authors:  Graham J Moore; Harry Ridgway; Konstantinos Kelaidonis; Christos T Chasapis; Irene Ligielli; Thomas Mavromoustakos; Joanna Bojarska; John M Matsoukas
Journal:  Molecules       Date:  2022-07-29       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.